Host Rahul Chaturvedi speaks with Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb, about how causal human biology, genetics, novel targets, and emerging technologies are reshaping drug discovery.
Read More
In this episode of Biotech 2050, host Rahul Chaturvedi sits down with Nello Mainolfi, Founder, President & CEO of Kymera Therapeutics, to explore his journey from chemist and drug hunter to biotech founder, and the decade-long evolution of Kymera into a leader in targeted protein degradation.
Read More
AI is reshaping drug discovery, but real breakthroughs need more than powerful models. Rahul Chaturvedi speaks with Nick Myerberg of Braidwell on lessons from AlphaFold, AI drug discovery’s first wave, and how autonomous labs and proprietary data could transform how new medicines are developed.
Read More
Rahul Chaturvedi sits down with Robert Jacks, President & CEO of Sparrow Pharmaceuticals, to discuss leadership, biotech strategy, and his journey from civil engineering to CEO. Discover why building lasting value—not chasing acquisitions—is the key to long-term biotech success.
Read More
In this deeply personal and inspiring conversation, Mike Raab, President & Chief Executive Officer of Ardelyx, and Laura Williams, Chief Patient Officer, share how empathy, resilience, and patient advocacy have shaped both their careers and the culture of the company they’ve built.
Read More
At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry.
Read More
This episode is proudly sponsored by Quartzy.
At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment.
Read More
In this episode of Biotech 2050, recorded during JPM 2026 in San Francisco, host Alok Tayi speaks with Cary Claiborne, CEO of Adial Pharmaceuticals, about a new precision-medicine approach to tackling one of the world’s most widespread and undertreated conditions: alcohol use disorder.
Read More
This episode is proudly sponsored by Quartzy.
Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a powerful conversation at the intersection of biotech innovation, leadership, and personal transformation.
Read More
At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine.
Read More
At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and rare-disease drug development.
Read More
From managing a theme park in Canada to leading Boehringer Ingelheim’s U.S. business, Brian Hilberdink’s path is anything but typical. Live from JPM 2026, Alok Tayi explores how frontline sales shaped his leadership across obesity, kidney disease, oncology, and rare disorders.
Read More